ohm20,

Thank you for your excellent work.

I am continually impressed with the scope and depth of your knowledge and appreciate your contributions to this board.

This evening, we all heard Dr.NP conservatively speak of 20 indications in the ProActive video (he, and we all know there are more).

And a month or so ago, we all heard Dr.BP repeatedly indicate that the deeper understanding of the MOA learned as a byproduct of COVID would be enormously important for CytoDyn for future indications.

Yet, I sincerely doubt anyone at the company has put in the time and effort to meticulously research and assemble such a scholarly list of potential indications.

And now, with what we all hope are impressive trial results, the CytoDyn will likely begin partnership discussions with 5 (five) World Wide Pharma companies -- and 6 (six) Regional Pharma Companies (Brazil, China, India, Europe, Middle East, Northern Africa).

I can't help but wonder if now would be a good time for you to share your impressive list with: Dr.NP, Dr.BP, Dr.JL, and Dr.SK.

Your indication list might very well impact the scope of discussions with these Pharma companies and may actually lead to material improvements in these agreements.

Thanks for considering this.

And thanks for your excellent work.